Nicox and Kowa sign agreement for exclusive rights to glaucoma treatment NCX 470
Under the terms of the agreement, Kowa receives exclusive rights to develop and commercialize NCX 470 in the US and all other territories of the world excluding Japan, China, Korea, and Southeast Asia.
Lupin launches loteprednol etabonate ophthalmic suspension, 0.5%, in the United States
Loteprednol etabonate ophthalmic suspension, 0.5% is bioequivalent to lotemax ophthalmic suspension, 0.5%, of Bausch & Lomb.
Part 3: Looking back at 50 years of innovation in ophthalmology
To mark Ophthalmology Times' 50th anniversary, we invited top experts to reflect on the most significant innovations in ophthalmology over the past five decades.
OKYO Pharma announces positive results from phase 2 trial of urcosimod for neuropathic corneal pain
Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor.
Children with ADHD may be less likely to develop myopia, study suggests
Authors noted it may be worthwhile to explore whether oral methylphenidate affects myopia by influencing dopamine levels
Harrow enters into agreement with Samsung Bioepis for commercial rights to its ophthalmology biosimilar portfolio
Included in the agreement are ranibizumab-nuna 0.05 mL injection (BYOOVIZ), referencing LUCENTIS (ranibizumab), and aflibercept-yszy 0.05 mL injection (OPUVIZ), referencing EYLEA (aflibercept).
AAVantgarde Bio receives IND clearance for AAVB-039
AAVB-039 advances gene therapy for Stargardt disease, aiming for innovative treatments for inherited retinal disorders.
FDA accepts for review Aldeyra Therapeutics’ resubmitted New Drug Application for reproxalap
A Prescription Drug User Fee Act (PDUFA) target action date of December 16, 2025, was assigned by the FDA.
FDA grants fast track designation to Sanofi’s SAR446597
SAR446597 is a one-time intravitreal gene therapy treatment for the treatment of geographic atrophy
Study links secondhand smoke exposure to increased myopia risk in children
A Chinese study reveals that secondhand smoke exposure significantly increases the risk of early-onset myopia in children
Part 2: Looking back at 50 years of innovation in ophthalmology
KAIST announces new microbe development for lutein production
KAIST researchers unveil a new microbial strain for efficient, eco-friendly lutein production.
Apellis announces 5 abstracts to be orally presented at the American Society of Retina Specialists (ASRS) annual meeting
Presentation highlights include 48-month data from the OAKS and DERBY trials as well as the GALE open-label extension.
New RainDrop Dispenser Aid aims to simplify use of single-use eye drops
The tool is designed to help with the application of mono-dose, dry eye eyedrop vials more easily and accurately.
Survey data shows trends for AMD and DME treatments and future prospects
The survey shows the evolving landscape of nAMD and DME treatments, highlighting physician preferences, payer influences, and the promise of gene therapy advancements.
MidWest Eye Center among first in Midwest to adopt new noncontact laser for glaucoma
Alcon’s Voyager is a fully automated, noncontact treatment approach that delivers 120 laser pulses through the limbus of the trabecular meshwork.
Nanoscope Therapeutics initiates rolling submission of BLA to FDA for MCO-010
MCO-010 is a gene-agnostic therapy for retinitis pigmentosa.
Looming US trade tariffs could disrupt optical industry
New tariffs threaten the optical industry, prompting urgent reevaluation of sourcing strategies and pricing as deadlines approach.
Krystal Biotech doses first patient in EMERALD-1 phase 1/2 trial for neurotrophic keratitis
Krystal Biotech initiates EMERALD-1 trial for KB801, a redosable eye drop gene therapy.
Part 1: Looking back at 50 years of innovation in ophthalmology
KALA Bio completes enrollment of CHASE clinical trial
KALA Bio completes enrollment in CHASE trial, advancing KPI-012 for treating persistent corneal epithelial defects. Topline results are expected by the end of Q3 2025.
Navigate successful cataract surgery with refractive technology
Careful management of patient expectations is key to achieving optimal outcomes.
LIGHTHOUSE study of ATSN-201 expanded to continuous phase 1/2/3 trial following FDA feedback
Alcon’s Clareon PanOptix Pro IOL approved in Canada for cataract patients
Alcon's Clareon Panoptix Pro IOL enhances cataract surgery with advanced light utilization and low visual disturbance.
Belite Bio completes enrollment in global phase 3 PHOENIX trial for geographic atrophy
The trial will evaluate the safety and tolerability of Tinlarebant and its potential to reduce atrophic lesion growth rate in patients diagnosed with GA in dry AMD.
Study data link cannabis use to lower risk of proliferative vitreoretinopathy after retinal detachment repair
50 years of ophthalmology: What changed the game (Part 2)
Ophthalmologists discuss the most impactful advancements reshaping patient care over five decades.
PulseSight doses first patient in PST-611-CT1
Preliminary results of PST-611-CT1 are anticipated early 2026, subject to patient recruitment.
50 years of ophthalmology: What changed the game (Part 1)
In honor of Ophthalmology Times’ 50th anniversary, anterior segment surgeons attending ASCRS 2025 weigh in on the innovations that defined modern ophthalmology.
Precautionary recall announced for specific batch of Zaditen eye drops in the UK
MHRA issues precautionary recall for Zaditen eye drops due to potential microbial contamination risk